EphA2-derived epitopes can induce the elevated immunoreactivity of CD4+ and CD8+ T cells in the EphA2-positive renal cell carcinoma (10), and dendritic cell vaccination with EphA2 peptides has been applied in the clinical trial of glioblastoma multiforme (11). This evidence concerns the gene EPHA2 and renal cell carcinoma.